-
Dec 5, 2024 | 
espanol.medscape.com | Meg Barbor
El American College of Obstetricians and Gynecologists (ACOG) ha actualizado sus recomendaciones de detección del cáncer de mama y sugiere que las personas con un riesgo promedio de presentar cáncer de mama comiencen a hacerse una mamografía a los 40 años.
-
Oct 25, 2024 | 
oncpracticemanagement.com | Jason Lockard |Meg Barbor
Korinne G. Lee, MSN, FNP-C1; Amanda Pate, MSN, RN-BC, OCN, ONS1; Bob Gold2; Jeff Rusk1; Chevon Rariy, MD1
1Oncology Care Partners; 2GoMo Health
Providing oncology care outside the clinic walls, where most side effects take place, can be extremely challenging.
-
Oct 18, 2024 | 
mdedge.com | Meg Barbor
The American College of Obstetricians and Gynecologists (ACOG) has updated its breast cancer screening guidelines, recommending that individuals at an average risk for breast cancer initiate mammography screening at age 40. This change reflects evolving evidence that starting earlier screening yields greater net benefits in reducing breast cancer mortality, particularly for certain racial groups with higher risk factors.
-
Sep 6, 2024 | 
theoncologypharmacist.com | Meg Barbor |Charlie Dawson |Chase Doyle
"Encourage Your Patients to Participate! US-Based Clinical Trials That Are Actively Recruiting in Ovarian Cancer" was originally published by Oncology Practice Management.
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.
-
Jun 27, 2024 | 
theoncologypharmacist.com | Meg Barbor |Charlie Dawson |Chase Doyle
Get TOP in Your Inbox!
Stay up to date with the latest oncology pharmacy news and insights by subscribing to our eNewsletter.
-
Jun 27, 2024 | 
theoncologypharmacist.com | Meg Barbor |Charlie Dawson |Chase Doyle
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.
-
Jun 26, 2024 | 
theoncologypharmacist.com | Meg Barbor |Charlie Dawson |Colleen Hall
BOSTON—Imagine a circle, with healthcare providers, researchers, and community partners such as churches making up the outer ring. In the center, picture a patient with cancer. All of those groups working together is the key to boosting clinical trial engagement, particularly in underrepresented populations, according to a panel of speakers at NCODA’s 6th Annual Oncology Institute meeting held in Boston in August.
-
Jun 26, 2024 | 
oncpracticemanagement.com | Patricia A. Stewart |Meg Barbor |Colleen Hall
BOSTON—Imagine a circle, with health care providers, researchers, and community partners such as churches making up the outer ring. In the center, picture a patient with cancer. All of those groups working together is the key to boosting clinical trial engagement, particularly in underrepresented populations, according to a panel of speakers at NCODA’s 6th Annual Oncology Institute meeting held here this week.
-
Apr 15, 2024 | 
oncpracticemanagement.com | Meg Barbor
The landscape of oncology treatment has witnessed a remarkable shift toward the use of oral medications over the past 2 decades driven by advancements in the understanding of molecular alterations as well as the ability to identify actionable mutations within cancer cells.
-
Jan 19, 2024 | 
mdedge.com | Meg Barbor
Primary aldosteronism (PA) is a frequently overlooked yet common cause of secondary hypertension, presenting significant risk for cardiovascular morbidity and mortality. But fewer than 4% of at-risk patients receive the recommended screening for PA, leaving a substantial gap in early detection and management, according to Adina F. Turcu, MD, MS, associate professor in endocrinology and internal medicine at University of Michigan Health in Ann Arbor.
